Matchmaking & Expertise Session: New Antimicrobial Drugs and Vaccines

The first HERMES session focuses on the development of new antimicrobial drugs and vaccines. 

During the session, 11 organisations from across Europe will present their expertise, technologies and capabilities, and what they can contribute to future European consortia. As a participant, you will have the opportunity to identify complementary expertise, find potential consortium partners and make new connections for future project proposals. 

Who should attend? 

The session is aimed at companies and organisations planning to participate in upcoming Horizon Europe calls and other European research and innovation programmes, whether you are looking to build a consortium, join one or find specific expertise to strengthen a project idea. 

Join to: 

• Discover expertise and capabilities relevant to upcoming calls  

• Identify potential partners for your consortium  

• Explore how different organisations could contribute to future projects  

• Connect with companies, research organisations and innovation actors across Europe  

• Start conversations that could develop into future Horizon Europe proposals  

Calls in focus 

This HERMES session is particularly relevant for organisations interested in forming consortia and preparing proposals for: 

• HORIZON-HLTH-2027-01-DISEASE-05 
  Development of novel broad spectrum small molecule antiviral therapeutics for pathogens with epidemic potential  

• HORIZON-HLTH-2027-01-DISEASE-06 
  Development of monoclonal antibodies to prevent and treat infections from Flaviviridae  

• HORIZON-HLTH-2027-01-DISEASE-07 
  Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga Viridae  

• HORIZON-HLTH-2027-01-DISEASE-08 
  Development of innovative antimicrobials against critical pathogens resistant to antimicrobials  

• OHAMR 2027  

Meet potential partners and complementary expertise 

The first HERMES session brings together 11 organisations from across Europe with expertise relevant to the development of antimicrobial drugs and vaccines: 

• Center for Research in Biological Chemistry and Molecular Materials, Santiago de Compostela, Spain  

• European Vaccine Initiative, Heidelberg, Germany  

• Global Antibiotic Research & Development Partnership, Geneva, Switzerland  

• Health-Ecore, Groningen, the Netherlands  

• Institute of Marine Research, Bergen, Norway  

• Ribocure Pharmaceuticals, Mölndal, Sweden  

• RISE Research Institutes of Sweden, Borås, Sweden  

• Sahlgrenska University Hospital, Gothenburg, Sweden  

• Scientific Institute for Hospitalization and Care for Infectious and Tropical Diseases, Negrar, Italy  

• University of Edinburgh, Edinburgh, UK  

• Veirulence, London, UK  

Each organisation will give a short expert presentation focusing on its core expertise, technologies and capabilities, potential contributions to future European consortia, and the types of partnerships and roles it is seeking. 

Presenter names and presentation titles will be published shortly. 

Programme 

14:00–14:10 Welcome and introduction 
Introduction to HERMES and the funding opportunities in focus. 

14:10–15:10 Presentation block 1 
Short presentations from the participating organisations focusing on expertise, capabilities and potential contributions to future consortia. 

15:10–15:20 Short break 

15:20–16:20 Presentation block 2 
Short presentations from the participating organisations focusing on expertise, capabilities and potential contributions to future consortia. 

16:20 Closing and next steps 

About HERMES 

HERMES – Horizon Europe Matchmaking and Expertise Session is a meeting series organised by RISE to strengthen European collaboration and facilitate early consortium building for upcoming Horizon Europe calls and other European research and innovation programmes. 

By making relevant expertise and capabilities visible at an early stage, HERMES aims to help organisations find complementary partners and create new opportunities for collaborative project development.